Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 23, 2014, 09:37:01 AM

Login with username, password and session length


Members
  • Total Members: 23759
  • Latest: JV
Stats
  • Total Posts: 643212
  • Total Topics: 48939
  • Online Today: 219
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Bionor Pharma's "Kick, Kill & Boost" Strategy-- Romidepsin Chosen as Kick  (Read 1935 times)

0 Members and 1 Guest are viewing this topic.

Offline Tadeys

  • Member
  • Posts: 159
Oslo 10.09.2013 - Bionor Pharma ASA (OSE: BIONOR) announces that the Company has chosen romidepsin for the planned combination study with Vacc-4x, after considering various HDAC inhibitors (HDACi). Romidepsin is marketed in the US as Istodax® by Celgene Corporation Inc.

The "Kick, Kill" study is planned to be conducted by the HIV research team at
Aarhus University Hospital, led by Prof. Lars Østergaard. Prof.  Østergaard
presented the background and expectations of the study at Bionor Pharma's
Capital Markets Day in June.

"HDAC inhibitors have recently shown the ability to release HIV from the
lymphatic system where the virus hides, and positive data from this new HDAC
inhibitor research will be published shortly" says Prof. Østergaard. He
continues; "The combination of providing Bionor Pharma's T-cell killing vaccine
Vacc-4x, followed by an HDAC inhibitor may represent a new treatment that can
completely or periodically enable patients to forego continuous treatment with
HIV medications, and thereby lead to a Functional Cure. Romidepsin is chosen
because it has proven to be the most effective HDAC inhibitor to release HIV
from virus reservoirs where virus is hiding. We are very positive about this
study which represents a new way to treat HIV, and have expectations that this
can improve the current treatment of HIV".

"Bionor Pharma is excited about the cooperation with the HIV scientists at
Aarhus University Hospital, who are in the forefront within this novel field of
HIV research" says Dr. Anker Lundemose, CEO Bionor Pharma. "Vacc-4x has
previously demonstrated  its ability to induce killing of virus producing cells
by training the immune system, which seems to be essential as soon as an HDAC inhibitor has activated such cells from being dormant in the reservoir".

Bionor Pharma will be the sponsor for the combination study at Aarhus University Hospital, and the plan is to submit the application with study protocol to the Danish Health Authorities by Q4 2013. Bionor Pharma filed patents on the combination of its vaccines with other treatment modalities including IMiD and HDACi earlier this year. The original romidepsin patent has expired.

The execution of the new "Kick Kill & Boost" strategy depends on funding of the
Vacc-4x & HDACi combination trial. To this end, the Company continues to
evaluate various strategic and financial opportunities, and will continue to
update the market on these efforts during H2 2013.

http://www.bionorpharma.com/en/News/2013/Scientific/Bionor+Pharma's+%22Kick,+Kill+%26+Boost%22+Strategy+Advances+-+Romidepsin+Chosen+as+the+%22Kick%22.b7C_wlvMX7.ips

Offline Matts

  • Member
  • Posts: 223
Re: Bionor Pharma's "Kick, Kill & Boost" Strategy-- Romidepsin Chosen as Kick
« Reply #1 on: November 19, 2013, 04:57:38 PM »
I am quite disappointed in the Scandinavians. What a PR-disaster with the Panobinostat trial in the Summer ("HIV cure on the brink" bla bla ). At least they could publish the results before they start a new project. Did it work or not?

Anyway, I wish Ole Soogard and Bionor the best for the future. If Istadax doesn't work then it's over for Bionor and Aarhus regarding to HIV. It is 1000-20000 fold stronger than SAHA. Maybe it will be the breakthrough :)

http://www.catie.ca/en/treatmentupdate/treatmentupdate-196/hiv-cure-research/promise-romidepsin
http://clinicaltrials.gov/ct2/show/NCT01933594
http://www.isheid.com/presentations/vendredi/12-30/geleziunas/Geleziunas.pdf
http://www.thebodypro.com/content/71626/the-promise-of-romidepsin.html
tivicay/kivexa

Offline Matts

  • Member
  • Posts: 223
The first results are in :)
OMG These Marketing-guys, You cant tell if it is good or not. I decide to be totally neutral:)

http://www.bionorpharma.com/en/News/2014/Scientific/Bionor+Pharma+Announces+Successful+Completion+of+Part+A+of+REDUC+Study%3B+First+Evidence+that+Romideps.b7C_wlvWYY.ips


http://clinicaltrials.gov/ct2/show/NCT02092116

The study is completed in December 2015, so You better wait.


"Bionor Pharma Announces Successful Completion of Part A of REDUC Study; First Evidence that Romidepsin “Kicks” HIV out of Reservoirs


•HDAC inhibitor (HDACi) Istodax® (romidepsin) successfully reactivated (“kick”) HIV in patients
•Treatment of Istodax® was safe and well tolerated
•Part B of the REDUC study to enroll patients in Q2 2014

(Oslo, Norway, 12 May 2014)  Bionor Pharma ASA (OSE: BIONOR) announces that the part A of the REDUC study has successfully completed. The objective of part A of the study was to establish the optimal dose of the HDACi Istodax® (romidepsin) based on safety and the effect on HIV reactivation. Treatment with 5mg/m2 of romidepsin was successfully able to reactivate HIV in 6 patients while on conventional HIV medication cART. Both cell-associated un-spliced HIV RNA as well as extracellular HIV RNA were significantly increased as a result of romidepsin infusion. The treatment was safe and most adverse events (AEs) were of grade 1. Two grade II AEs in one individual were observed. No serious adverse events were observed.

Data from part A of the study will be submitted to the upcoming international AIDS society (IAS) conference meeting.

The objective of part B of the REDUC trial is to investigate the effect on the HIV latent reservoir and viral load by combining Vacc-4x vaccination with romidepsin reactivation of HIV. Researchers refer to this approach as a “Kick-kill” strategy, where the HDACi is used to “kick” the virus out of reservoirs making the HIV infected cells visible to the immune system; the immune response generated by Vacc-4x will be able to attack and eliminate the infected cells. Conventional HIV medication, cART is shown not to be able to address the virus in reservoirs and sanctuary regions.

Enrollment of patients for part B is expected to start in Q2 2014.

"As predicted by pre-clinical work, it is comforting to know that romidepsin can reactivate latent HIV reservoirs in patients,” said Professor Lars Østergaard, Aarhus University Hospital, the Principal Investigator of this trial. “We are pleased with today’s results, and this looks very promising for the key objective of the trial exploring the potential reduction of the latent HIV reservoirs by Vacc-4x vaccination following by romidepsin activation,” continued Professor Lars Østergaard. “Especially the significant detection of HIV RNA in plasma by a standardized and routine RT-PCR assay indicates a strong ability of romidepsin to activate the reservoir.”

About the REDUC trial
The REDUC trial will study the combination of the HDAC inhibitor Istodax® and Vacc-4x in HIV patients on combination antiretroviral therapy (cART).  The first phase of the study established the optimal dose of Istodax® based on safety and the effect on latent reservoirs. The second phase will include vaccination with Vacc-4x followed by treatment with Istodax® once a week for three weeks. Patients will then have a protocol specified cART treatment interruption for 18 weeks.   During this period without cART the control of HIV replication will be evaluated to see if the viral load continues to be suppressed by the immune system. Bionor Pharma is the study sponsor. The Department of Infectious Diseases, Aarhus University Hospital, Denmark with Lead investigator Professor Lars Østergaard will be conducting the study. Enrollment of patients into the study is planned for Q2 2014.

About Bionor Pharma ASA
Bionor Pharma is a leading biotechnology company, searching for breakthrough products for the treatment and prevention of life-threatening viral diseases. The Company is listed on the Oslo Stock Exchange, and is developing vaccines for viral infections. The vaccines are based on a proprietary technology platform developed following more than two decades of research into peptides, and they are designed to safely stimulate the immune system to combat viral diseases. 

More information about Bionor Pharma is available at www.bionorpharma.com.

Bionor Pharma ASA
CFO Synne H Røine, Norway Tel +47 99 22 98 92
David Sheon, USA  Tel  +1 202 422-6999
tivicay/kivexa

Offline tryingtostay

  • Member
  • Posts: 233
This sounds like the best approach to me.  Where do I sign up!

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.